Atypical CML: The Rare, Aggressive Blood Cancer Defying Treatment

Atypical chronic myeloid leukemia (aCML) is a rare and aggressive form of blood cancer. It accounts for just 1% to 2% of all chronic myeloid leukemia (CML) cases, with only 103 diagnoses recorded in the U.S. between 2016 and 2020. Unlike typical CML, aCML progresses faster and proves harder to diagnose and treat. aCML belongs to a group of conditions known as myelodysplastic/myeloproliferative (MDS/MPN) neoplasms. In this disease, bone marrow cells multiply uncontrollably, producing abnormal and immature white blood cells called blasts. Doctors diagnose aCML by checking for specific blood cell counts, the presence of immature myeloid precursors, and the absence of certain genetic rearrangements.

Symptoms of aCML vary but often include fatigue, weakness, and unexplained weight loss. Patients may also experience anemia, bruising, bleeding, and frequent infections. Other signs are shortness of breath, pale skin or gums, headaches, and lightheadedness. Treatment options depend on the patient's condition. Some receive erythropoiesis-stimulating agents or cytoreductive drugs to manage symptoms. Others undergo chemotherapy or, in eligible cases, hematopoietic stem cell transplantation—the only potentially curative approach. Despite treatment, aCML generally has a poorer outlook than typical CML. One study found a median overall survival of just 10.8 months.

aCML remains a challenging disease due to its rarity and aggressive nature. Stem cell transplants offer the best chance for a cure, but eligibility is limited. Early diagnosis and tailored treatment plans are critical for improving patient outcomes.